DK2040713T3 - Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande - Google Patents

Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande

Info

Publication number
DK2040713T3
DK2040713T3 DK07809913.2T DK07809913T DK2040713T3 DK 2040713 T3 DK2040713 T3 DK 2040713T3 DK 07809913 T DK07809913 T DK 07809913T DK 2040713 T3 DK2040713 T3 DK 2040713T3
Authority
DK
Denmark
Prior art keywords
fxr
prevention
treatment
conditions
acid derivatives
Prior art date
Application number
DK07809913.2T
Other languages
Danish (da)
English (en)
Inventor
Roberto Pellicciari
Stefano Fiorucci
Mark Pruzanski
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2040713(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2040713T3 publication Critical patent/DK2040713T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07809913.2T 2006-06-27 2007-06-27 Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande DK2040713T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81663506P 2006-06-27 2006-06-27
PCT/US2007/014829 WO2008002573A2 (en) 2006-06-27 2007-06-27 Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions

Publications (1)

Publication Number Publication Date
DK2040713T3 true DK2040713T3 (da) 2014-09-29

Family

ID=38846269

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07809913.2T DK2040713T3 (da) 2006-06-27 2007-06-27 Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande

Country Status (14)

Country Link
US (4) US7932244B2 (enExample)
EP (1) EP2040713B1 (enExample)
JP (1) JP5222846B2 (enExample)
CN (1) CN101522703B (enExample)
AU (1) AU2007265457C1 (enExample)
CA (1) CA2656320C (enExample)
CY (1) CY1115533T1 (enExample)
DK (1) DK2040713T3 (enExample)
ES (1) ES2523591T3 (enExample)
IL (2) IL196169A (enExample)
PL (1) PL2040713T3 (enExample)
PT (1) PT2040713E (enExample)
SI (1) SI2040713T1 (enExample)
WO (1) WO2008002573A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303399T1 (de) 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
DK2712617T3 (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010014836A2 (en) * 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
DK2376519T3 (da) 2008-11-19 2014-02-03 Intercept Pharmaceuticals Inc TGR5-modulatorer og fremgangsmåde til anvendelse deraf
US9339480B2 (en) 2008-11-26 2016-05-17 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
EP2379081B1 (en) 2008-12-19 2013-03-20 Royal College of Surgeons in Ireland Treatment of diarrhoea
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
ITRM20100329A1 (it) * 2010-06-15 2011-12-16 Franco Baldelli Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2525223A1 (en) * 2011-05-19 2012-11-21 Universiteit Maastricht In vitro method for predicting in vivo genotoxicity of chemical compounds.
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
EA201990211A1 (ru) 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
MX361653B (es) * 2012-10-26 2018-12-13 Intercept Pharmaceuticals Inc Procedimiento para la preparación de derivados del ácido biliar.
KR102106186B1 (ko) * 2012-11-28 2020-05-04 인터셉트 파마슈티컬즈, 인크. 폐 질환의 치료
ES2847002T3 (es) * 2013-05-14 2021-07-30 Intercept Pharmaceuticals Inc Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
NZ716568A (en) * 2013-08-01 2021-07-30 Us Health Inhibitors of the farnesoid x receptor and uses in medicine
AU2014320463B2 (en) 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
MX356006B (es) * 2013-10-18 2018-04-24 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
EP3071696B1 (en) 2013-11-22 2019-08-07 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
RS64050B1 (sr) 2014-05-29 2023-04-28 Bar Pharmaceuticals S R L Derivati holana za upotrebu u lečenju i/ili prevenciji fxr i tgr5/gpbar1 posredovanih bolesti
WO2016049069A1 (en) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
KR20170094184A (ko) * 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
DK3221333T3 (da) 2014-11-19 2019-09-30 Nzp Uk Ltd 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086115A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PT3277286T (pt) 2015-03-31 2021-07-01 Enanta Pharm Inc Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes
PE20180034A1 (es) 2015-04-07 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas
WO2016173493A1 (en) * 2015-04-28 2016-11-03 Shanghai De Novo Pharmatech Co. Ltd. Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
EP3124080A1 (en) 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetic bile acids for injection lipolysis
WO2017053428A1 (en) 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
KR20180052756A (ko) * 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
EP3359160B1 (en) * 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
US20170233431A1 (en) * 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN109152840A (zh) 2016-03-28 2019-01-04 英特塞普特医药品公司 通过结合fxr激动剂和arb获得的药物
CA3020698A1 (en) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating or preventing hepatocellular carcinoma
JP6963882B2 (ja) 2016-05-05 2021-11-10 チルドレンズ ホスピタル メディカル センター 胃底部組織のインビトロでの製造のための方法及び当該方法と関連した組成物
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN109963567A (zh) * 2016-09-30 2019-07-02 英特塞普特医药品公司 胆汁酸衍生物的结晶形式
EP3534907A4 (en) 2016-11-04 2020-06-24 Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASE
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
WO2018102418A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US20180256600A1 (en) * 2017-03-07 2018-09-13 Intercept Pharmaceuticals, Inc. Methods of treating cancer
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
PT4122464T (pt) 2017-03-28 2024-06-27 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças do fígado
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
CN111050772A (zh) 2017-07-24 2020-04-21 英特塞普特医药品公司 同位素标记的胆汁酸衍生物
EP3679139B1 (en) 2017-09-08 2022-11-02 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
CA3077442A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
SG11202100533VA (en) 2018-07-26 2021-02-25 Childrens Hospital Med Ct Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11208571B2 (en) 2018-08-08 2021-12-28 University Of Maryland, College Park Methods for nondestructive dispersing of carbon nanomaterials in water
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
SG11202107434PA (en) 2019-01-15 2021-08-30 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
EP3920937A4 (en) * 2019-02-04 2022-11-02 Intercept Pharmaceuticals, Inc. TREATMENT AND PREVENTION OF INFLAMATORY BOWEL DISEASES WITH A BILE ACID DERIVATIVE
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
WO2020243590A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CN112142814B (zh) * 2019-06-26 2021-09-28 江苏吉贝尔药业股份有限公司 牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN119950519B (zh) * 2025-01-07 2025-11-21 山东省海洋科学研究院(青岛国家海洋科学研究中心) 奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5014206A (en) 1988-08-22 1991-05-07 Facilitech International Incorporated Tracking system
DE9011787U1 (de) 1990-08-14 1990-10-25 Fritz Schäfer GmbH, 5908 Neunkirchen Identifikationseinheit für Müllbehälter
US5121853A (en) 1991-07-30 1992-06-16 Waste Management Of North America Garbage container
DE9204254U1 (de) 1992-03-28 1992-06-17 Fritz Schäfer GmbH, 5908 Neunkirchen Müllbehälter, insbesondere Müllgroßraumbehälter, mit einer Identifikationseinheit
ZA947912B (en) 1993-10-12 1995-05-24 Broadbent J W Nominees Pty Ltd Treatment of medical disorders associated with free radical formation
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
US5565846A (en) 1994-04-25 1996-10-15 Indala Corporation Reader system for waste bin pickup vehicles
FR2784364B1 (fr) 1998-10-13 2000-12-15 Plastic Omnium Cie Bac pour la collecte de dechets, equipe d'un transpondeur
WO2000037077A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
US6448898B1 (en) 1999-12-16 2002-09-10 Cardinal Automation, Inc. System for auditing refuse collection
DE10030905C2 (de) 2000-06-24 2003-08-07 Der Gruene Punkt Duales Syst Verwendung von Transpondern bei der Dokumentation und Handhabung von Abfällen
ATE303399T1 (de) * 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
JP5384777B2 (ja) 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
US6975229B2 (en) 2002-08-09 2005-12-13 Battelle Memorial Institute K1-53 System and method for acquisition management of subject position information
US20040229453A1 (en) * 2003-05-15 2004-11-18 Jsr Micro, Inc. Methods of pore sealing and metal encapsulation in porous low k interconnect
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ES2523591T3 (es) 2006-06-27 2014-11-27 Intercept Pharmaceuticals Inc. Derivados de ácidos biliares como ligandos de FXR para la prevención o el tratamiento de enfermedades o estados mediados por FXR

Also Published As

Publication number Publication date
AU2007265457C1 (en) 2012-11-29
WO2008002573A3 (en) 2008-02-28
EP2040713A2 (en) 2009-04-01
IL221764A0 (en) 2012-10-31
CA2656320A1 (en) 2008-01-03
US20120283234A1 (en) 2012-11-08
JP5222846B2 (ja) 2013-06-26
US20140057886A1 (en) 2014-02-27
PL2040713T3 (pl) 2014-11-28
US8546365B2 (en) 2013-10-01
SI2040713T1 (sl) 2014-11-28
IL196169A (en) 2012-10-31
CY1115533T1 (el) 2017-01-04
US20080182832A1 (en) 2008-07-31
HK1130187A1 (en) 2009-12-24
EP2040713A4 (en) 2012-08-29
JP2010500285A (ja) 2010-01-07
ES2523591T3 (es) 2014-11-27
IL196169A0 (en) 2009-09-22
WO2008002573A2 (en) 2008-01-03
CN101522703B (zh) 2013-04-17
CA2656320C (en) 2015-04-28
PT2040713E (pt) 2014-10-13
IL221764A (en) 2016-09-29
US9090652B2 (en) 2015-07-28
AU2007265457B2 (en) 2012-06-14
AU2007265457A1 (en) 2008-01-03
US20150359805A1 (en) 2015-12-17
EP2040713B1 (en) 2014-06-18
CN101522703A (zh) 2009-09-02
US7932244B2 (en) 2011-04-26
US9763964B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
DK2040713T3 (da) Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
DK1984357T3 (da) 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
DK2207775T3 (da) 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
NO20091183L (no) Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
CY2016017I2 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
DK2178840T3 (da) Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2114386T3 (da) Farmaceutisk sammensætning til behandling af diabeteskomplikationer
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2459553T3 (da) Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
DK2249866T3 (da) Anvendelse af et acetylsalicylsyresalt til behandlingen af virusinfektioner